Sandu Pharmaceuticals

Mumbai, India Founded: 1899 • Age: 127 yrs Listed
Ayurvedic health and wellness products are manufactured in India.
Request Access
Report Incorrect Data
Page last updated

About Sandu Pharmaceuticals

Sandu Pharmaceuticals is a publicly listed company based in Mumbai (India) founded in 1899. Ayurvedic health and wellness products are manufactured in India. The company has 295 employees. Its website sandu.in draws about 38 thousand monthly visits. Its Indian entity Sandu Pharmaceuticals Limited reported revenue of ₹70.37 Cr. Sandu Pharmaceuticals offers products and services including Ayurvedic Medicines and Health Tonics. Its focus areas include Alternative Medicine Products.

Company details

Sandu Pharmaceuticals was established in 1899 in Mumbai, India, within the pharmaceuticals sector. Ayurvedic health and wellness products are produced, drawing from traditional Indian medicinal practices. Operations are centered on manufacturing these items, with distribution handled through the domain sandu.in. Leadership is provided by Managing Director Umesh Bhaskar Sandu, whose DIN is 01132141. The focus remains on ayurveda-based formulations for consumer health needs.

  • Headquarters Mumbai, India
  • Employees 295
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Alternative and Natural Medicine
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website sandu.in
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Sandu Pharmaceuticals Limited
Operational Areas
Healthcare → Alternative Medicine Products
Key Metrics
  • Market Cap
    ₹36.40 Cr

    SANDUPHQ · BSE

  • Share Price
    ₹37.90

    +0.58% today

  • Revenue
    ₹67.19 Cr

    FY 2024-25 · -0.1% YoY

  • EBITDA
    ₹2.77 Cr

    Margin 4.1%

  • Net Profit
    ₹1.56 Cr

    FY 2024-25 · +6.1% YoY

  • P/E (TTM)
    22.9x

    P/B 1.1x

  • ROE
    4.7%

    ROCE 6.9%

  • Employee Count
    295

Products & Services of Sandu Pharmaceuticals

Sandu Pharmaceuticals offers a comprehensive portfolio of products and services, including Ayurvedic Medicines and Health Tonics.

Ayurvedic Medicines
Health Products

A variety of Ayurvedic medicines is offered for conditions such as digestive health and respiratory care, based on traditional herbal formulations

Health Tonics
Wellness Supplements

Health tonics are provided for vitality and immunity, incorporating ingredients like Ashwagandha and Arjunarishta to support overall well-being

Apps and channels of Sandu Pharmaceuticals

its YouTube channel Sandu Pharma has 8.57K subscribers and 30 videos.

Sandu Pharma
YouTube 8.57K subscribers 30 videos People & Blogs
Open channel

Videos from Sandu Pharmaceuticals

The most watched videos on Sandu Pharmaceuticals's YouTube channel, Sandu Pharma (8.57K subscribers). Click a video to play it here.

Dr. Suvinay Damle talks about our products!
917 views
Dr Ashwini Shetty's Sandu Products Testimonial!
888 views
Vaidya Satkar Samaroh - 2023 by Sandu Pharma Pharmaceuticals | Dr Nilesh Londhe
628 views
Dr. Buta Ram Nihal Singh talks about his experience with our products!
380 views

More on Sandu Pharma.

Board of directors of Sandu Pharmaceuticals Limited (Sandu Pharmaceuticals)

Sandu Pharmaceuticals Limited is the primary company behind Sandu Pharmaceuticals. The board of Sandu Pharmaceuticals Limited currently have 5 directors; the longest-serving is Shashank Bhaskar Sandu, appointed in 2011. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Shashank Bhaskar Sandu
DIN 00678098
Director01 Jun 201115 yrs 5 moSandu Pharmaceuticals Limited
Balram Viswanathan
DIN 10245195
Director14 Aug 20233 yrs 2 moSandu Pharmaceuticals Limited
Ajit Rajaram Kantak
DIN 10269866
Director14 Aug 20233 yrs 2 moSandu Pharmaceuticals Limited
Vijay Kottapalli
DIN 10245156
Director12 Aug 20242 yrs 3 moSandu Pharmaceuticals Limited
Jayshree Bhasker Sandu
DIN 07480177
Director30 Sep 20242 yrs 1 moSandu Pharmaceuticals Limited

People of Sandu Pharmaceuticals

4 people are tracked at Sandu Pharmaceuticals (2 in leadership, 2 in team); the tracked headcount is 295.

NameRoleGroup
Umesh Bhaskar Sandu
Managing DirectorLeadership
Shashank Sandu
DirectorLeadership
Krishna B Deshpande
Leadership / ManagementTeam
Shri Dilip R Salgaoncar
Leadership / ManagementTeam
Premium access

Complete people profiles for Sandu Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sandu Pharmaceuticals

Sandu Pharmaceuticals is a publicly listed company on the BSE with ticker symbol SANDUPHQ in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date12 Sep 1994
  • Listed onBSE: 524703
  • Listed entitySandu Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE751D01014
  • Share price₹35.90 (+3.61% on the day) · 2026-10-14
  • Market capitalisation₹33.5 Cr
  • Price to earnings19.6
  • EPS (diluted, trailing year)₹1.83
  • Dividend yield2.74%
  • Volume (last session)14

Financials of Sandu Pharmaceuticals

Exchange-reported figures of Sandu Pharmaceuticals Limited, the listed company behind Sandu Pharmaceuticals (BSE: SANDUPHQ).

Financial Highlights

FY 2024-25 · Consolidated
Revenue
₹67.19 Cr
-0.1% YoY
EBITDA
₹2.77 Cr
+20.4% YoY
Profit After Tax
₹1.56 Cr
+6.1% YoY
Net Worth
₹42.02 Cr
+3.5% YoY
Total Assets
₹42.44 Cr
+4.4% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue67.1967.2865.35
Revenue growth-0.1%+3.0%-
EBITDA2.772.302.48
EBITDA margin+4.1%+3.4%+3.8%
Profit before tax2.172.082.21
Net profit1.561.471.52
Net profit margin+2.3%+2.2%+2.3%
EPS (₹)1.611.511.57
Balance sheet
Total assets42.4440.6539.24
Net worth42.0240.5939.24
Total debt0.000.000.00
Cash & bank2.651.212.30
Net working capital14.2211.6711.66
Cash flow
Cash from operations0.950.760.22
Cash from investing(0.19)(1.31)0.54
Cash from financing(0.46)(0.72)0.58
ParticularsMar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
Revenue14.0718.3717.7017.0515.6017.4316.6117.66
Revenue growth (YoY)-9.8%+5.4%+6.6%-3.5%+2.2%---
Other income0.070.020.030.040.310.030.090.00
EBITDA0.450.990.910.410.610.510.830.36
EBITDA margin+3.2%+5.4%+5.1%+2.4%+3.9%+2.9%+5.0%+2.0%
Depreciation0.150.190.170.160.190.140.130.12
Interest0.030.030.030.020.010.020.010.02
Profit before tax0.340.790.740.270.720.380.780.22
Tax0.010.240.240.110.120.170.210.10
Net profit0.330.550.500.160.600.210.570.12
EPS (₹)0.340.571.950.170.620.210.570.11
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue69.9367.1967.2865.3565.5058.7648.37
Revenue growth+4.1%-0.1%+3.0%-0.2%+11.5%+21.5%-
EBITDA2.992.762.302.482.882.151.45
EBITDA margin+4.3%+4.1%+3.4%+3.8%+4.4%+3.7%+3.0%
Profit before tax2.642.162.082.212.321.670.92
Net profit1.751.551.471.521.591.080.72
Net profit margin+2.5%+2.3%+2.2%+2.3%+2.4%+1.8%+1.5%
EPS (₹)1.831.601.511.581.801.381.02
Balance sheet
Total assets44.0942.4940.6639.2436.4733.5130.48
Net worth43.6742.0240.5939.2436.4733.4929.24
Total debt0.110.060.000.000.000.021.25
Cash & bank6.862.651.202.294.1711.661.54
Net working capital15.0114.2711.6611.6611.7718.0512.32
Cash flow
Cash from operations6.120.950.760.220.957.596.20
Cash from investing(0.57)(0.18)(1.31)0.53(5.47)(5.58)(0.37)
Cash from financing(0.94)(0.46)(0.72)0.580.931.30(5.36)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16.3916.8518.7617.6216.7014.0718.3717.70
Revenue growth (YoY)-1.9%+19.8%+2.1%-0.5%-2.1%---
Other income0.020.370.010.050.020.070.020.03
Total expenses15.8516.2817.7216.7616.1713.6217.3816.79
EBITDA0.540.571.040.860.530.450.990.91
EBITDA margin+3.3%+3.4%+5.5%+4.9%+3.2%+3.2%+5.4%+5.1%
Depreciation0.160.160.170.170.180.150.190.17
Interest0.030.030.030.030.030.030.030.03
Profit before tax0.370.750.850.710.340.340.790.74
Tax0.130.70(0.12)0.190.120.010.240.24

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
ParticularsMar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
Revenue14.0718.3717.7017.0515.6017.4316.6117.66
Revenue growth (YoY)-9.8%+5.4%+6.6%-3.5%+2.2%---
Other income0.070.020.030.040.310.030.090.00
EBITDA0.450.990.910.410.610.510.830.36
EBITDA margin+3.2%+5.4%+5.1%+2.4%+3.9%+2.9%+5.0%+2.0%
Depreciation0.150.190.170.160.190.140.130.12
Interest0.030.030.030.020.010.020.010.02
Profit before tax0.340.790.740.270.720.380.780.22
Tax0.010.240.240.110.120.170.210.10
Net profit0.330.550.500.160.600.210.570.12
EPS (₹)0.340.571.950.170.620.210.570.11
ParticularsFY 2024-25FY 2023-24FY 2022-23
Revenue67.1967.2865.35
Revenue growth-0.1%+3.0%-
Other income0.170.420.33
Total expenses64.4264.9862.87
Employee cost10.9210.0711.10
EBITDA2.772.302.48
EBITDA margin+4.1%+3.4%+3.8%
Depreciation0.670.580.52
Interest0.100.060.08
Profit before tax2.172.082.21
Tax0.610.610.69
Net profit1.561.471.52
Net profit margin+2.3%+2.2%+2.3%
EPS (₹)1.611.511.57
ParticularsFY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital9.669.669.66
Reserves & surplus32.3630.9329.58
Shareholders' funds (net worth)42.0240.5939.24
Minority interest0.000.000.00
Secured loans0.000.000.00
Unsecured loans0.000.000.00
Total debt0.000.000.00
Total liabilities42.4440.6539.24
Assets
Gross block30.2929.3527.51
Net block18.1517.8816.62
Capital work in progress0.000.000.42
Investments11.2210.429.65
Inventories14.1512.2514.33
Sundry debtors4.764.874.79
Cash & bank balances2.651.212.30
Loans & advances4.743.984.13
Total current assets26.3022.3125.55
Total current liabilities12.0810.6413.89
Net working capital14.2211.6711.66
Total assets42.4440.6539.24
ParticularsFY 2024-25FY 2023-24FY 2022-23
Opening cash1.002.280.94
Net cash from operating activities0.950.760.22
Net cash from investing activities(0.19)(1.31)0.54
Net cash from financing activities(0.46)(0.72)0.58
Net change in cash0.30(1.27)1.34
Closing cash2.651.212.30
ParticularsFY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth-0.1%+3.0%-
EBITDA growth+20.4%-7.3%-
PBT growth+4.3%-5.9%+9997.0%
Net income growth+6.1%-3.3%-
Profitability & leverage
Net income margin+2.3%+2.2%+2.3%
Return on capital employed+6.9%+6.0%+5.9%
Return on net worth+4.7%+4.1%+3.9%
Debt / equity0.000.000.00
Long-term debt / equity0.000.000.00
Interest cover4.763.494.08
Efficiency & per share
Fixed asset turnover3.172.792.38
Inventory turnover5.095.064.56
Debtors turnover13.9513.9313.64
EPS (₹)1.611.511.57
Dividend per share (₹)0.800.800.00
Book value per share (₹)34.6333.0140.62
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue16.3916.8518.7617.6216.7014.0718.3717.70
Revenue growth (YoY)-1.9%+19.8%+2.1%-0.5%-2.1%---
Other income0.020.370.010.050.020.070.020.03
Total expenses15.8516.2817.7216.7616.1713.6217.3816.79
EBITDA0.540.571.040.860.530.450.990.91
EBITDA margin+3.3%+3.4%+5.5%+4.9%+3.2%+3.2%+5.4%+5.1%
Depreciation0.160.160.170.170.180.150.190.17
Interest0.030.030.030.030.030.030.030.03
Profit before tax0.370.750.850.710.340.340.790.74
Tax0.130.70(0.12)0.190.120.010.240.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue69.9367.1967.2865.3565.5058.7648.37
Revenue growth+4.1%-0.1%+3.0%-0.2%+11.5%+21.5%-
Other income0.440.170.420.330.080.190.45
Total expenses66.9464.4364.9862.8762.6256.6146.92
Employee cost10.6910.9210.0711.108.918.026.85
EBITDA2.992.762.302.482.882.151.45
EBITDA margin+4.3%+4.1%+3.4%+3.8%+4.4%+3.7%+3.0%
Depreciation0.680.670.580.520.530.560.55
Interest0.110.100.060.080.110.110.43
Profit before tax2.642.162.082.212.321.670.92
Tax0.890.610.610.690.730.590.20
Net profit1.751.551.471.521.591.080.72
Net profit margin+2.5%+2.3%+2.2%+2.3%+2.4%+1.8%+1.5%
EPS (₹)1.831.601.511.581.801.381.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.669.669.669.668.817.927.08
Reserves & surplus34.0132.3630.9329.5827.2224.6722.16
Shareholders' funds (net worth)43.6742.0240.5939.2436.4733.4929.24
Secured loans0.000.000.000.000.000.021.25
Unsecured loans0.110.060.000.000.000.000.00
Total debt0.110.060.000.000.000.021.25
Total liabilities44.0942.4940.6639.2436.4733.5130.48
Assets
Gross block30.9630.2929.3527.5126.3826.0225.89
Net block18.1218.1517.8816.6216.0116.1816.60
Capital work in progress0.060.000.000.420.480.000.00
Investments12.3011.2210.439.669.110.240.82
Inventories10.4714.1512.2514.3311.2711.1414.36
Sundry debtors5.414.764.874.793.995.354.68
Cash & bank balances6.862.651.202.294.1711.661.54
Loans & advances2.594.743.984.134.212.401.83
Total current assets25.3326.3022.3025.5423.6430.5522.41
Total current liabilities10.3212.0310.6413.8811.8712.5010.09
Net working capital15.0114.2711.6611.6611.7718.0512.32
Total assets44.0942.4940.6639.2436.4733.5130.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.301.002.270.944.531.220.74
Net cash from operating activities6.120.950.760.220.957.596.20
Net cash from investing activities(0.57)(0.18)(1.31)0.53(5.47)(5.58)(0.37)
Net cash from financing activities(0.94)(0.46)(0.72)0.580.931.30(5.36)
Net change in cash4.600.31(1.27)1.33(3.59)3.310.48
Closing cash6.862.651.202.294.1711.661.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.1%-0.1%+3.0%-0.2%+11.5%+21.5%-
EBITDA growth+8.3%+20.0%-7.3%-13.9%+34.0%+48.3%-
PBT growth+22.2%+3.9%-5.9%-4.7%+38.9%+81.5%-8.0%
Net income growth+12.9%+5.4%-3.3%-4.4%+47.2%+50.0%-
Revenue CAGR (3Y)+2.3%+0.9%+4.6%+10.6%+9.8%+6.2%+4.2%
EBITDA CAGR (3Y)+6.4%-1.4%+2.3%+19.6%+11.5%-4.4%-7.8%
Profitability & leverage
Net income margin+2.5%+2.3%+2.2%+2.3%+2.4%+1.8%+1.5%
Return on capital employed+8.0%+6.9%+6.0%+6.9%+9.4%+7.9%+4.8%
Return on net worth+5.2%+4.7%+4.1%+4.6%+6.1%+4.9%+3.0%
Debt / equity0.000.000.000.000.000.030.15
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover4.764.783.494.084.686.9247.78
Efficiency & per share
Fixed asset turnover3.163.172.792.913.823.502.28
Inventory turnover5.685.095.065.115.854.613.50
Debtors turnover13.7513.9513.9314.8914.0311.7210.20
EPS (₹)1.831.601.511.581.801.381.02
Dividend per share (₹)0.000.800.800.000.750.500.00
Book value per share (₹)36.4834.6233.0140.6230.7129.6328.22

Web traffic of Sandu Pharmaceuticals

The website of Sandu Pharmaceuticals (sandu.in) receives about 37.6K visits a month and ranks #569,979 among all websites worldwide, #480 in Alternative and Natural Medicine.

  • Monthly visits
    37.6K

    ▼ 41% vs previous month

  • Unique visitors
    33.9K

    per month

  • Global rank
    #569,979

    among all websites

  • Category rank
    #480

    Health · Alternative and Natural Medicine

Similar websites

Websites whose visitors overlap most with Sandu Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
baidyanath.co
baidyanath.co
100%
#331,595–
Sreedhareeyam
sreedhareeyam.com
100%
34.4K#759,965View details
Ayurdhama
ayurdhama.com
98%
17.7K#1,568,487View details
Baidyanath Ayurved
baidyanathayurved.com
97%
#131,729View details
Zandu Care
zanducare.com
95%
1.4M#36,644View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Sandu Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Alternative Medicine Products

3 companies that operate in the same segment as Sandu Pharmaceuticals (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Schwabe India
Homeopathic medicine manufacturing and online retail in India.
1898Noida, Uttar Pradesh, IndiaUSD 26.35 M1,192
Healthmug
Operates an online store specializing in ayurvedic and homeopathic medicines.
2016Delhi, Delhi, IndiaUSD 1.25 M16
Jiva Ayurveda
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness.
1992Faridabad, Haryana, IndiaUSD 10.08 M570
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sandu Pharmaceuticals

Sandu Pharmaceuticals standalone net profit rises 4.55% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 3 months ago
SANDUPHQ: Q1 FY27 revenue reached ₹1,638.88 lakhs with net profit at ₹22.82 lakhs and EPS at ₹0.37
Quartr • 3 months ago
SANDUPHQ: FY26 saw higher revenue, profit, and cash, with a Rs. 1 dividend and no large borrowings
Quartr • 6 months ago
SANDUPHQ: Revenue and profit rose, dividend declared, and new leadership and auditor appointed
Quartr • 6 months ago
SANDUPHQ: Q3 FY26 saw higher revenue and profit, with EPS at ₹1.01 and a single-segment focus
Quartr • 9 months ago
SANDUPHQ: Q2 FY26 saw higher revenue, improved profit, and robust cash flow in Ayurvedic medicines
Quartr • 1 year ago
SANDUPHQ: Q1 FY26 saw higher revenue and profit, with AGM and dividend record date set for September
Quartr • 1 year ago
Sandu Pharmaceuticals consolidated net profit declines 44.07% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
SANDUPHQ: FY25 saw steady profit growth, a dividend proposal, and a shift to standalone reporting
Quartr • 1 year ago
SANDUPHQ: Net profit rose 4.02% to ₹154.89 lakhs on stable revenue; 8% dividend recommended
Quartr • 1 year ago
Premium access

Complete news archive for Sandu Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sandu Pharmaceuticals

Sandu Pharmaceuticals was founded in 1899.

Sandu Pharmaceuticals is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Sandu Pharmaceuticals has 295 employees.

The primary company behind Sandu Pharmaceuticals, Sandu Pharmaceuticals Limited, reported revenue of ₹70.37 Cr for FY 2026, up 4% year on year.

Sandu Pharmaceuticals was established in 1899 in Mumbai, India, within the pharmaceuticals sector. Ayurvedic health and wellness products are produced, drawing from traditional Indian medicinal practices. Operations are centered on manufacturing these items, with distribution handled through the domain sandu.in. Leadership is provided by Managing Director Umesh Bhaskar Sandu, whose DIN is 01132141. The focus remains on ayurveda-based formulations for consumer health needs.

Sandu Pharmaceuticals offers Ayurvedic Medicines and Health Tonics.

Yes, Sandu Pharmaceuticals is publicly traded on BSE under the ticker symbol SANDUPHQ.

Sandu Pharmaceuticals operates through Sandu Pharmaceuticals Limited.

The legal entities of Sandu Pharmaceuticals currently have 7 directors, including Shashank Bhaskar Sandu, Pratika Mhambray, Jayshree Bhasker Sandu and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available